IMR Press / FBL / Volume 19 / Issue 6 / DOI: 10.2741/4254

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
The role of the ubiquitin-proteasome pathway in cancer development and treatment
Show Less
1 Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2014, 19(6), 886–895; https://doi.org/10.2741/4254
Published: 1 June 2014
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
Abstract

Ubiquitination is a post-translational modification that plays a role in several cellular processes including cell cycle progression, cell proliferation, DNA replication and apoptosis. Ubiquitin-mediated signaling is frequently altered in cancer cells. Several tumor suppressors and oncogenes interact with enzymes of the ubiquitinproteasome pathway that function in ubiquitin conjugation and deconjugation. Increasing evidence indicates that the ubiquitin-proteasome system (UPS) plays an important role in cancer development. Several small molecule inhibitors of the UPS have been applied to the treatment of cancer. The current review focuses on the role of the UPS in cancer development and the development of UPS inhibitors for cancer treatment.

Keywords
Ubiquitination
Ubiquitin-Proteasome System
Cancer
Review
Share
Back to top